Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

Carmen Hidalgo-Tenorio
* ORCID logo ,
Juan Pasquau
,
David Vinuesa
,
Sergio Ferra
ORCID logo ,
Alberto Terron
,
Isabel SanJoaquin
,
Antoni Payeras
,
Onofre Juan Martinez
,
Miguel Ángel Lopez-Ruz
,
Mohamed Omar
,
Javier de la Torre-Lima
,
Ana Lopez-Lirola
,
Jesus Palomares
,
Jose Ramón Blanco
ORCID logo ,
Marta Montero
ORCID logo ,
Coral Garcia-Vallecillos
Version 1 : Received: 7 February 2022 / Approved: 9 February 2022 / Online: 9 February 2022 (10:45:33 CET)

A peer-reviewed article of this Preprint also exists.

Hidalgo-Tenorio, C.; Pasquau, J.; Vinuesa, D.; Ferra, S.; Terrón, A.; SanJoaquín, I.; Payeras, A.; Martínez, O.J.; López-Ruz, M.Á.; Omar, M.; de la Torre-Lima, J.; López-Lirola, A.; Palomares, J.; Blanco, J.R.; Montero, M.; García-Vallecillos, C. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). Viruses 2022, 14, 524. Hidalgo-Tenorio, C.; Pasquau, J.; Vinuesa, D.; Ferra, S.; Terrón, A.; SanJoaquín, I.; Payeras, A.; Martínez, O.J.; López-Ruz, M.Á.; Omar, M.; de la Torre-Lima, J.; López-Lirola, A.; Palomares, J.; Blanco, J.R.; Montero, M.; García-Vallecillos, C. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). Viruses 2022, 14, 524.

Abstract

Background: Objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: Open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with 48-week follow-up. Results: The study included 88 PLHIV (91% male) with mean age of 35.9 years; 76.1% were MSM. Mean baseline CD4 was 516.4 cells/uL, with viral load (VL) of 104,828 cop/mL, and 11.4% were in AIDS stage. DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I+E138A, and V108I); 12.5% were lost to follow-up. At week 48, 86.3% had VL< 50 cop/uL by intention-to-treat analysis and 98.7% by per-protocol (PP) analysis. Virological failure (VF) was recorded in 1.1%, with no resistance mutation. One blip was detected in 5.2%, without VF. Three reported anxiety, dizziness, and cephalgia, respectively, at week 4 and one insomnia at week 24; none reported adverse events at week 48. Mean weight was 4 kg higher at 48 weeks (p=0.0001) and abdominal circumference 3 cm larger at 24 weeks (p=0.022). No forgetfulness occurred in 98.7% of patients. Patient satisfaction was 90/100 at 4, 24, and 48 weeks. Conclusion: Real-world data demonstrate that dolutegravir plus lamivudine in MTR is effective, safe, and satisfactory, moderately increasing weight and abdominal circumference and administrable on a test-and-treat strategy.

Keywords

DOLAVI; Dolutegravir; Lamivudine; Real World Data; HIV

Subject

Medicine and Pharmacology, Immunology and Allergy

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.